Theravance Inc. (THRX) and GlaxoSmithKline (GSK) announced the initial outcomes from Phase III studies of once-daily Relovair Monday morning.
Theravance gapped open sharply lower Monday and has continued to fall on above average volume in early trade. The stock is now down 7.19 at $13.01 and has dropped to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.